Under active development. Data is being added and corrected on an hourly basis.

← Back to Peptides
Tabimorelin structure

Tabimorelin

Growth Hormone
Phase 2 Research
50%
Moderate Risk
3/5

Warnings

STRONG CYP3A4 inhibitor - major drug interactions
Development discontinued for safety
Research use only

Contraindications

PregnancyBreastfeedingLiver Disease

Drug Interactions

CYP3A4 SubstratesStatinsImmunosuppressantsAnticoagulants

Possible Side Effects

Increased AppetiteWater RetentionParesthesiasFatigue

Legal & Regulatory

FDA Status Not FDA Approved
WADA Status Prohibited in Sport
Prescription Not Required

Pregnancy

Category X - Contraindicated